MedVasc secures SEK 24 Million financing and advances Solutio™ toward FDA clearance
Cathrin Johansson, CEO, and Michael Åkesson, founder of MedVascLund, Sweden – MedVasc AB has successfully completed production and testing activities in accordance with its previously communicated plan. In parallel, the company closed a new financing round at the end of 2025, raising SEK 24 million through subscriptions exclusively from existing shareholders.
”The strong participation from current owners demonstrates continued confidence in MedVasc’s strategy, execution capability, and long-term value creation. The board and management view this support as a clear validation of the company’s direction and its ongoing development efforts,” says Cathrin Johansson, CEO of MedVasc.
With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio™ for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026.
For more information, please contact:
Cathrin Johansson, CEO, MedVasc AB
cathrin.johansson@medvasc.se
www.medvasc.se
About Solutio™
Solutio™ is developed to provide painless and precise local anesthesia during thermal treatment of venous insufficiency. The anesthesia catheter is compatible with so-called gold standard treatment fibers (RF/Laser) worldwide.
MedVasc is a member of SmiLe Venture Hub.
About SmiLe Venture Hub – Pioneering Life Science and Foodtech Innovations
SmiLe is a leading venture hub that specializes in advancing life science and foodtech startups from concept to commercialization. We offer comprehensive support through every stage of entrepreneurship, including tailored incubation and acceleration programs, a variety of educational courses, and access to top-tier lab facilities. To date, our flagship incubator program has supported over 120 startups, facilitating their collective acquisition of more than EUR 1.22 billion in venture capital and contributing to 21 successful IPOs. Recognized as one of Europe’s leading startup hubs in 2024 by the Financial Times and Statista, SmiLe continues to be a catalyst for innovation in the life sciences sector. As a non-profit entity based in Lund, Sweden, SmiLe is supported by Region Skåne, Lund Municipality, Lund University, and Medicon Village. We are also backed by our partners Agilent, Sparbanken Skåne, Høiberg, Setterwalls, Zacco, Key2Compliance, Phase Holographic Imaging, ChemoMetec, Samplix, Qiagen, Bio-Rad, Zeiss, SmartStone Nordics, Säkra, Servier and AbbVie Scandinavia. For more information: www.smileventurehub.com
Powered by Notified